SCHEMBL29124862

SCHEMBL29124862

CCSc1nc(NC(=O)OC(C)(C)C)c2nc[nH]c2n1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.36
▸ L3MBTL1 Q9Y468 3/20 0.35
▸ SCN9A Q15858 1/20 0.34
▸ SIRT2 Q8IXJ6 1/20 0.34
▸ AURKA O14965 1/20 0.33
▸ AURKB Q96GD4 1/20 0.33
▸ MAPT P10636 2/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ P4HB P07237 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ ATM Q13315 1/20 0.31
▸ ADORA3 P0DMS8 1/20 0.31
▸ ADORA1 P30542 1/20 0.31
▸ STK17B O94768 1/20 0.31
▸ STK17A Q9UEE5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29124864 0.87 CCNE1 (0.41) SYKL3MBTL1ALDH1A1
SCHEMBL29124870 0.87 SYK (0.37) SYKL3MBTL1SCN9AAURKAAURKB
SCHEMBL29124861 0.85 IDO1 (0.42) SCN9ASIRT2AURKAAURKBMAPT
SCHEMBL29124863 0.84 CXCR2 (0.39) L3MBTL1SIRT2AURKAAURKBMAPT
SCHEMBL19738205 0.80 SYK (0.39) SYKL3MBTL1AURKAMAPTTDP1
SCHEMBL19738337 0.80 SYK (0.39) SYKL3MBTL1MAPTTDP1NPSR1
SCHEMBL22939319 0.80 SYK (0.39) SYKL3MBTL1MAPTTDP1
SCHEMBL29593210 0.80 SYK (0.39) SYKL3MBTL1MAPTTDP1
SCHEMBL29124874 0.80 SYK (0.39) SYKL3MBTL1AURKAAURKBGAA
SCHEMBL19738339 0.79 SYK (0.39) SYKL3MBTL1MAPTTDP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368164-A1 PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF ASTROCYTE PHARMACEUTICALS, INC. 2024-11-07 — — US disclosed
EP-4329773-A1 PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF Astrocyte Pharmaceuticals, Inc. (US) 2024-03-06 — — EP disclosed
CN-117241803-A Purine nucleosides, intermediates and methods of making the same 阿斯特罗赛特制药公司 2023-12-15 — — CN disclosed
WO-2022232810-A1 PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF ASTROCYTE PHARMACEUTICALS, INC. (US) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368164-A1 PURINE NUCLEOSIDES, THEIR INTERMEDIATES, AND METHODS OF PREPARATION THEREOF NUDT1, PNP, UMPS SYK 3749/4885L3MBTL1 1589/4885SCN9A 4007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback